Efficacy and safety of Kanglaite injection for gastric cancer
A protocol for systematic review and meta-analysis
Daorui Hou, MS[8,9], Liangjun Yang, MD[8], Jian Xiong, MM[8], Lu Xiong, MD[8,9]*

Abstract
Background: Kanglaite injection is a broad-spectrum anti-tumor drug, which is extracted from the seeds of the Chinese medicinal herb Coix lacryma-jobi, and has been widely used for the treatment of gastric cancer (GC). This study aimed to systematically investigate the efficacy and safety of Kanglaite injection for the treatment of GC.

Methods: We will perform the comprehensive literature search in English and Chinese electronic database from its inception to June 2020. Two trained researchers will independently select the qualified studies for data extraction and assess the quality and risk of bias. Cochrane Risk of Bias tool will be used to assess the risk of bias of included studies. The outcomes included overall response rate, complete response rate, 3-year progression-free survival rate, 3-year overall survival rate, and different types of treatment-related adverse events. Funnel plot analysis and Egger test will be used to assess the publication bias. Finally, the quality of evidence will be assessed by the grading of recommendations assessment, development, and evaluation system. We will calculate the risk ratio as well as their 95% confidence intervals of these outcomes and pool the results using RevMan 5.4 software and STATA 16.0 software.

Results: The results of our research will be published in a peer-reviewed journal.

Conclusion: The conclusion of our systematic review will provide evidence to judge whether Kanglaite injection is an effective intervention for patient with GC.

OSF registration number: 10.17605/OSF.IO/HF679.

Abbreviations: GC = gastric cancer, KLT = Kanglaite, RCTs = randomized controlled trials.

Keywords: Kanglaite, gastric cancer, protocol, systematic review and meta-analysis

1. Introduction
Gastric cancer (GC) is the fifth most frequently diagnosed cancer and the third leading cause of cancer death, which was responsible for over 1,000,000 new cases in 2018 and an estimated 783,000 deaths.[1,2] Despite recent advances in therapeutic methods including surgery combined with chemotherapy and radiotherapy, the prognosis for advanced GC patients remains very poor.[3] With high incidence and mortality rate, GC causes a serious health burden globally, especially in several Western Asian and Eastern Asia countries (eg, in Mongolia, Japan, and the Republic of Korea).[2,4] Thus, implementation of a multimodality treatment approach is of great significance to further improve survival.[5]

Traditional Chinese medicine has been used for thousands of years and is widely used as an alternative or combined treatment for cancers.[6–9] Various natural products from Chinese herbal extracts exhibit strong inhibitory properties against carcinogenesis.[10] As one of famous Chinese herb, Coix seed is well known for its anti-tumor and immunomodulatory effects.[11,12] In recent years, Coix seed and its extracts have been used to treat many diseases such as cancer, arthritis, hypertension, asthma, and immunological disorders.[13–15]

In 1995, Kanglaite injection, which is extracted from the seeds of the Chinese medicinal herb Coix lacryma-jobi, was approved by the State Food and Drug Administration of China (Drug Approval Number: Z10970091) for the treatment of various cancers. It is also the first Chinese medicine approved by the US Food and Drug Administration, and has been used as a biphase broad-spectrum antitumor drug in clinical trials in the United States.[16,17] Millions cancer patients in more than 2000 hospitals in China have been treated with Kanglaite injection.[18] It has
been widely used for the treatment of Pancreatic cancer,[19,20] lung cancer,[21,22] breast cancer,[23] colorectal cancer,[24] hepato-cellular carcinoma,[25] and GC.[26,27] Researches showed that Kanglaite injection could effectively reverse multiple-drug resistance in cancer cells and enhance the sensitivity of tumor cells to chemotherapeutic drugs.[17,27–29]

With the publication of numbers of trials and clinical studies on Kanglaite injection for GC, there is an urgent need for a systematic review to assess the effectiveness and safety of Kanglaite injection in treating GC. Hereby, the aim of our study is to systematically review current available randomized controlled trials (RCTs) and to objective comment the efficacy and safety of Kanglaite injection treatment of GC.

2. Methods and analysis

2.1. Study registration

This systematic review will be conducted followed the guideline of the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols recommendations.[32] This work has been registered at Open Science Framework (OSF, https://osf.io/), an open-source project management that helps in the design of studies. The registration DOI of this study is 10.17605/OSF.IO/HF679.

2.2. Eligibility criteria

2.2.1. Study design. RCTs which used Kanglaite injection or a combination of Kanglaite injection and routine pharmacotherapy as treatment measures will be eligible. Nonrandomized control studies, qualitative studies, laboratory studies, and observational study will be excluded in the review. Language will be limited to English and Chinese.

2.2.2. Types of participants. Trials included adult (18 years or older) participants of any ethnic origin, gender, nationality who had GC. Individuals with other malignancies and non-primary GC will be excluded.

2.2.3. Types of interventions. Interventions to be reviewed are Kanglaite injection alone or combinations with other interventions to treat the GC. When Kanglaite injection used as combinations with other treatments, the control group should also receive the same combination treatments.

2.2.4. Outcomes. The primary outcomes of this analysis include overall survival and progression-free survival. Overall response rate, disease control rate, and adverse events are defined as the secondary outcomes.

2.3. Search strategy

2.3.1. Electronic searches. To identify all relevant studies, a comprehensive electronic search of the following databases including 4 English medics database and 4 Chinese databases will be performed from their inception to June 2020: PubMed, Embase, MEDLINE, Cochrane Library Central Register of Controlled Trials, China National Knowledge Infrastructure database, Wanfang Data Knowledge Service Platform, Chinese Scientific Journals Database, Chinese Biomedical Literature Service System (SinoMed). An example of search strategy for PubMed database that combines MeSH terms and free words will be adopted. The search strategy was as follows:

#1 Search: (“Stomach Neoplasms”[Mesh]) OR ((((((((Cancers, Stomach)[Title/Abstract]) OR (Gastric Cancers)[Title/Abstract]) OR (Stomach Neoplasms)[Title/Abstract]) OR (Gastric Neoplasms)[Title/Abstract]) OR (Cancers, Stomach)[Title/Abstract]) OR (Cancers, Gastric)[Title/Abstract]) OR (Cancer, Stomach)[Title/Abstract]) OR (Cancer, Stomach)[Title/Abstract]) OR (Cancer of the Stomach)[Title/Abstract]) OR (Stomach Cancer)[Title/Abstract]) OR (Gastric Cancer)[Title/Abstract]) OR (Cancers, Gastric)[Title/Abstract]) OR (Cancers, Stomach)[Title/Abstract]) OR (Cancers, Stomach)[Title/Abstract]) OR (Cancer of the Stomach)[Title/Abstract]) OR (Cancer of the Stomach)[Title/Abstract]) OR (Cancer of the Stomach)[Title/Abstract]) OR (Stomach Neoplasms)[Title/Abstract]) OR (Gastric Neoplasms)[Title/Abstract]) OR (Cancers, Stomach)[Title/Abstract]) OR (Cancers, Gastric)[Title/Abstract]) OR (Cancers, Stomach)[Title/Abstract]) OR (Cancers, Stomach)[Title/Abstract]) OR (Cancer of the Stomach)[Title/Abstract]) OR (Cancer of the Stomach)[Title/Abstract]) OR (Cancer of the Stomach)[Title/Abstract]) OR (Stomach Neoplasms)[Title/Abstract]) OR (Gastric Neoplasms)[Title/Abstract]) OR (Cancers, Stomach)[Title/Abstract]) OR (Cancers, Gastric)[Title/Abstract]) OR (Cancers, Stomach)[Title/Abstract]) OR (Cancers, Stomach)[Title/Abstract]) OR (Cancer of the Stomach)[Title/Abstract]) OR (Cancer of the Stomach)[Title/Abstract]) OR (Cancer of the Stomach)[Title/Abstract]) OR (Stomach Neoplasms)[Title/Abstract]) OR (Gastric Neoplasms)[Title/Abstract]) OR (Cancers, Stomach)[Title/Abstract]) OR (Cancers, Gastric)[Title/Abstract]) OR (Cancers, Stomach)[Title/Abstract]) OR (Cancers, Stomach)[Title/Abstract]) OR (Cancer of the Stomach)[Title/Abstract]) OR (Cancer of the Stomach)[Title/Abstract]) OR (Cancer of the Stomach)[Title/Abstract]) OR (Stomach Neoplasms)[Title/Abstract]) OR (Gastric Neoplasms)[Title/Abstract]) OR (Cancers, Stomach)[Title/Abstract]) OR (Cancers, Gastric)[Title/Abstract]) OR (Cancers, Stomach)[Title/Abstract]) OR (Cancers, Stomach)[Title/Abstract]) OR (Cancer of the Stomach)[Title/Abstract]) OR (Cancer of the Stomach)[Title/Abstract]) OR (Cancer of the Stomach)[Title/Abstract]) OR (Stomach Neoplasms)[Title/Abstract]) OR (Gastric Neoplasms)[Title/Abstract]) OR (Cancers, Stomach)[Title/Abstract]) OR (Cancers, Gastric)[Title/Abstract]) OR (Cancers, Stomach)[Title/Abstract]) OR (Cancers, Stomach)[Title/Abstract]) OR (Cancer of the Stomach)[Title/Abstract]) OR (Cancer of the Stomach)[Title/Abstract]) OR (Cancer of the Stomach)[Title/Abstract]) OR (Stomach Neoplasms)[Title/Abstract]) OR (Gastric Neoplasms)[Title/Abstract]) OR (Cancers, Stomach)[Title/Abstract]) OR (Cancers, Gastric)[Title/Abstract]) OR (Cancers, Stomach)[Title/Abstract]) OR (Cancers, Stomach)[Title/Abstract]) OR (Cancer of the Stomach)[Title/Abstract]) OR (Cancer of the Stomach)[Title/Abstract]) OR (Cancer of the Stomach)[Title/Abstract]) OR (Stomach Neoplasms)[Title/Abstract]) OR (Gastric Neoplasms)[Title/Abstract]) OR (Cancers, Stomach)[Title/Abstract]) OR (Cancers, Gastric)[Title/Abstract]) OR (Cancers, Stomach)[Title/Abstract]) OR (Cancers, Stomach)[Title/Abstract]) OR (Cancer of the Stomach)[Title/Abstract]) OR (Cancer of the Stomach)[Title/Abstract]) OR (Cancer of the Stomach)[Title/Abstract]) OR (Stomach Neoplasms)[Title/Abstract]) OR (Gastric Neoplasms)[Title/Abstract]) OR (Cancers, Stomach)[Title/Abstract]) OR (Cancers, Gastric)[Title/Abstract]) OR (Cancers, Stomach)[Title/Abstract]) OR (Cancers, Stomach)[Title/Abstract]) OR (Cancer of the Stomach)[Title/Abstract]) OR (Cancer of the Stomach)[Title/Abstract]) OR (Cancer of the Stomach)[Title/Abstract]) OR (Stoma
blinding, incomplete outcome data, and selective outcome reporting, participants, interventions in experimental group and control group, outcome indicators, and adverse events. Important missing data will be obtained by contacting article authors whenever possible. Data extraction will be completed independently by paired reviewers. If there is a conflict, the third reviewer (Liangjun Yang) will resolve it by organizing discussions.

2.4.3. Assessment of risk of bias in included studies. Two independent reviewers (Daorui Hou and Liangjun Yang) will evaluate the risk of bias for each study using the Cochrane Collaboration's tool, an established and reliable tool for assessing the risk of bias. In this tool, the risk of bias of a trial is assessed through 6 items, including selection bias, performance bias, detection bias, attrition bias, reporting bias, and other sources of bias. The assessment will be classified into 3 levels: “Low risk,” “High risk,” or “Unclear risk.” Disagreements between the 2 reviewers will be resolved by a third reviewer (Lu Xiong) during the evaluation of bias assessment.

2.4.4. Synthesis of data. Statistical analyses will be performed using RevMan 5.4 (Cochrane, London, UK) and STATA 16.0 software. For dichotomous variables, the risk ratio will be applied to analyze. For continuous variables, a mean difference or a standard mean difference will be used for analysis. Mean difference will be used when the treatment outcome was measured by the same scale. Standard mean difference will be used when the treatment outcome was measured by different scales in different studies. The confidence intervals for both dichotomous and continuous variables will be set to 95%.

2.4.5. Assessment of heterogeneity. To assess the statistical heterogeneity of evidence, the chi-squared ($\chi^2$) test and the inconsistency index ($I^2$) statistic. If $P \geq 0.05$ and $I^2 \leq 50\%$, it suggests that no statistical heterogeneity is observed between subgroups, and the Mantel–Haenszel fixed model will be
employed for meta-analysis. If $P<0.05$ and $I^2 > 50\%$, it is considered that there is great heterogeneity between the studies, and the random effect model will be used. Subgroup analysis, meta-regression, or descriptive analysis will be used for heterogeneity analysis.\cite{133} The results will be showed in tables and figures when the quantitative synthesis is not suitable.

2.4.6. Sensitivity analysis. A sensitivity analysis for primary outcomes will be performed to evaluate the robustness of the review conclusions if feasible. We will exclude each study included in the analysis. Then we will re-analyze and compile the data. The difference between the re-obtained effects and the original effects will be compared.

2.4.7. Grading the quality of evidence. The Grading of Recommendations Assessment, Development, and Evaluation, a widely used tool in evaluating the quality of assessment, will be applied to assess the quality level of evidence by 2 reviewers (Daorui Hou and Liangjun Yang).\cite{136} The quality of evidence will be assorted into “high,” “moderate,” “low,” and “very low” quality.\cite{137} Disagreements between the 2 reviewers will be resolved by a third reviewer (Lu Xiong).

2.4.8. Publication bias. When more than 10 studies are included, a funnel plot will be used to identify the possible publication bias. Egg regression and Begger tests will be utilized to detect the funnel plot asymmetry.\cite{138} $P < 0.05$ is considered to have publication bias.

2.5. Patient and public involvement

This part is not covered in this study.

2.6. Ethics and dissemination

This study will not need ethical approval because the data used are not linked to individual patient. The results of this review will be disseminated by being published in a peer-reviewed journal.

3. Discussion

GC, as a common cancer with high morbidity and mortality worldwide, requires continuous exploration for new treatment methods and concepts.\cite{139} Traditional Chinese medicine, a medicine with a history of thousands of years, has an irreplaceable role in the supplement and adjuvant treatment for GC.\cite{140,141} In recent years, Kanglaite injection has been widely used in the treatment of GC and has a significant effect on patients with GC.\cite{142,143} However, the evidence from RCTs is inconsistent. With an increasing number of clinical trials, it is urgent to systematically evaluate the efficacy of Kanglaite in the treatment of GC. In this study, we will summarize the up-to-date evidence of Kanglaite injection for the treatment of GC. This work may also provide helpful evidence to determine whether Kanglaite injection is effective and safe for patients with GC, which may benefit both clinical practice and health-related policy makers.

Author contributions

Conceptualization: Lu Xiong.
Data curation: Daorui Hou, Liangjun Yang, Jian Xiong.
Formal analysis: Liangjun Yang, Lu Xiong.
Funding acquisition: Lu Xiong.
Investigation: Daorui Hou, Jian Xiong.
Methodology: Daorui Hou, Liangjun Yang, Lu Xiong.
Project administration: Lu Xiong.
Resources: Daorui Hou, Liangjun Yang.
Software: Daorui Hou, Liangjun Yang.
Supervision: Lu Xiong.
Writing – original draft: Daorui Hou, Liangjun Yang.
Writing – review & editing: Daorui Hou, Liangjun Yang, Lu Xiong.

References

[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019;69:7–34.
[2] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424.
[3] Fu M, Gu J, Jiang P, et al. Exosomes in gastric cancer: roles, mechanisms, and applications. Mol Cancer 2019;18:41.
[4] Soerjomataram I, Lortet-Tieulent J, Parkin DM, et al. Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions. Lancet 2012;380:1840–50.
[5] Charalampakis N, Ekomomopoulos P, Kotsantis I, et al. Medical management of gastric cancer: a 2017 update. Cancer Med 2018;7:123–33.
[6] Tao WW, Jiang H, Tao XM, et al. Effects of acupuncture, Tuina, Tai Chi, Qigong, and traditional Chinese medicine five-element music therapy on symptom management and quality of life for cancer patients: a meta-analysis. Pain Manage Nurs 2016;17:728–47.
[7] Wu M, Lu P, Shi L, et al. Traditional Chinese patent medicines for cancer treatment in China: a nationwide medical insurance data analysis. Oncotarget 2015;6:38283–95.
[8] Xiang Y, Guo Z, Zhu P, et al. Traditional Chinese medicine as a cancer treatment: modern perspectives of ancient but advanced science. Cancer Med 2019;8:1958–73.
[9] Efferth T, Li PC, Konkimalla VS, et al. From traditional Chinese medicine to rational cancer therapy. Trends Mol Med 2007;13:533–61.
[10] Jiao L, Bi L, Lu Y, et al. Cancer chemoprevention and therapy using Chinese herbal medicine. Biol Proced Online 2018;20:1.
[11] Hidaka T, Kameda T, Amino N, et al. Chinese medicine, Coix seeds increase peripheral cytotoxic T and NK cells. Biotherapy 1992;5:201–3.
[12] Kameda T, Hidaka Y, Kashihara T, et al. Effect of coix seed on the changes in peripheral lymphocyte subsets. Rinsho Byori 1992;40:179–81.
[13] Yu YL, Lu Y, Tang X, et al. Formulation, preparation and evaluation of an intravenous emulsion containing Brucea javanica oil and Coix Seed oil for anti-tumor application. Biol Pharm Bull 2008;31:673–80.
[14] Yu F, Gao J, Zeng Y, et al. Inhibition of Coix seed extract on fatty acid synthase, a novel target for anti-cancer activity. J Ethnopharmacol 2008;119:252–8.
[15] Zeng W, Yin L, Shi L, et al. Pharmacological analysis of Modified Simiaow powder on gouty arthritis and hyperuricemia. Chin J Exp Tradit Med Formul 2014;20:129–33.
[16] Chao L, Chen J, Jing W. Effects of Kanglaite injection combined with NP chemotherapy for immune status, inflammatory factors and quality of life of patients with advanced NSCLC. J Int Oncol 2018;4:535–8.
[17] Zhang XW, Liu L, Zhang XZ, et al. Kanglaite inhibits the expression of drug resistance genes through suppressing PVT1 in cisplatin-resistant gastric cancer cells. Exp Ther Med 2017;14:789–94.
[18] Schwartzberg LS, Arena FP, Bienvenu B, et al. A randomized, open-label, safety and exploratory efficacy study of Kanglaite injection (KLTi) plus gemcitabine versus gemcitabine in patients with advanced pancreatic cancer. J Cancer 2017;8:1872–83.
[19] Zhang L, Lu J, Yang Z, et al. A meta-analysis of the efficacy and safety of Kanglaite injection combined with chemotherapy in the treatment of pancreatic cancer. Drug Combination Therapy 2019;9:210–23.
[20] Liu J, Yu L, Ding W. Efficacy and safety of Kanglaite injection combined with radiochemotherapy in the treatment of advanced pancreatic cancer: a PRISMA-compliant meta-analysis. Medicine (Baltimore) 2019;98:e16636.
[21] Wen J, Yang T, Wang J, et al. Kanglaite injection combined with chemotherapy versus chemotherapy alone for the improvement of clinical efficacy and immune function in patients with advanced...
non-small-cell lung cancer: a systematic review and meta-analysis. Evid-Based Compl Altern Med 2020:2020:8586596.

[22] Huang X, Wang J, Lin W, et al. Kanglai injection plus platinum-based chemotherapy for stage III/IV non-small cell lung cancer: a meta-analysis of 27 RCTs. Phytomedicine 2020;67:153154.

[23] Guo HY, Cai Y, Yang XM, et al. Randomized phase II trial on mitomycin-C/cisplatin +/- KLT in heavily pretreated advanced breast cancer. Am J Chin Med 2008;36:665–74.

[24] Wu J, Yang Z, Long F, et al. Effect and safety of Kanglai injection combined with chemotherapy in the treatment of advanced colorectal cancer: systematic review and meta-analysis. Asian Toxicol Res 2019;1:18–28.

[25] Liu J, Liu X, Ma J, et al. The clinical efficacy and safety of kanglai adjuvant therapy in the treatment of advanced hepatocellular carcinoma: a PRISMA-compliant meta-analysis. Biosci Rep 2019;39:BRS20193319.

[26] Zhan YP, Huang XE, Cao J, et al. Clinical safety and efficacy of Kanglai* (Coix Seed Oil) injection combined with chemotherapy in treating patients with gastric cancer. Asian Pac J Cancer Prev 2012;13:5319–21.

[27] Wang JC, Tian JH, Ge L, et al. Which is the best Chinese herb injection based on the FOLFOX regimen for gastric cancer? A network meta-analysis of randomized controlled trials. Asian Pac J Cancer Prev 2014;15:4795–800.

[28] Yang C, Hou A, Yu C, et al. Kanglai reverses multidrug resistance of HCC by inducing apoptosis and cell cycle arrest via PI3K/AKT pathway. Onco Targets Ther 2018;11:983–96.

[29] Wang Y, Zhang C, Zhang S, et al. Kanglai sensitizes colorectal cancer cells to Taxol via NF-κB inhibition and connexin 43 upregulation. Sci Rep 2017;7:1280.

[30] Bramer W, Bain P. Updating search strategies for systematic reviews using EndNote. J Med Libr Assoc 2017;105:285–9.

[31] Bramer WM. Reference checking for systematic reviews using Endnote. J Med Libr Assoc 2018;106:542–6.

[32] Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015;4:1.

[33] Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.

[34] Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539–58.

[35] Shuster JJ. Cochrane handbook for systematic reviews for interventions, Version 5.1. 0, published 3/2011. Julian PT Higgins and Sally Green. Research Synthesis Methods 2011;2:126–30.

[36] Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ 2004;328:1490.

[37] Guyatt GH, Oxman AD, Schünemann HJ, et al. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol 2011;64:380–2.

[38] Peters JL, Sutton AJ, Jones DR, et al. Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. J Clin Epidemiol 2008;61:991–6.

[39] Rawla P, Barsouk A. Epidemiology of gastric cancer: global trends, risk factors and prevention. Prz Gastroenterol 2019;14:26–38.

[40] Wang M, Tian Z, Zhu Y, et al. Sichong formula inhibits the proliferation and migration of human gastric cancer cells. Onco Targets Ther 2019;12:5741–50.

[41] Li J, Niu J, Yang M, et al. Using single-patient (n-of-1) trials to determine effectiveness of traditional Chinese medicine on chemotherapy-induced leukopenia in gastric cancer: a feasibility study. Ann Transl Med 2019;7:124.